Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Chetan Lathia"'
Autor:
Frank V. Fossella, George R. Blumenschein, Carol Peña, Chetan Lathia, Martin Reck, David J. Stewart
Publikováno v:
Cancer Biomarkers. 10:287-298
We investigated the relationship between plasma protein biomarker concentrations and clinical outcomes in 52 patients with relapsed/refractory advanced non-small cell lung cancer (NSCLC) treated with 400 mg bid sorafenib in a phase II trial. Blood sa
Publikováno v:
Clinical Cancer Research. 16:4853-4863
Purpose: Plasma proteins [vascular endothelial growth factor (VEGF), soluble VEGF receptor 2 (sVEGFR-2), carbonic anhydrase IX (CAIX), tissue inhibitor of metalloproteinase 1 (TIMP-1), and Ras p21] and one tumor gene (VHL) were analyzed to identify p
Autor:
Carol Peña, Salvatore Siena, Claudio Zamagni, Guenter Raab, Nicole Laferriere, Luca Gianni, Loredana Bergamini, Giulia Bianchi, Chetan Lathia, Stefania Salvagni, Sibylle Loibl
Publikováno v:
Anti-Cancer Drugs. 20:616-624
This trial was conducted to assess the efficacy and safety of sorafenib in patients with metastatic breast cancer. In this multinational, open-label phase II study, patients with metastatic breast cancer that had progressed after at least one prior c
Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors
Autor:
Eric Chen, Lillian L. Siu, M. Maclean, H. Hirte, Sebastien J. Hotte, John Wright, Gregory R. Pond, Ignacio Duran, Lixia Duan, Janet Dancey, S. Turner, Chetan Lathia, Scott Walsh
Publikováno v:
Clinical Cancer Research. 13:4849-4857
Purpose: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these d
Autor:
Hal W. Hirte, F. Cihon, L.L. Siu, Oana Petrenciuc, Brian Schwartz, Chetan Lathia, Michael J. Moore, Amit M. Oza, Sebastien J. Hotte
Publikováno v:
Annals of Oncology. 16:1688-1694
Background BAY 43--9006, an oral multi-kinase inhibitor, targets serine-threonine kinases and receptor tyrosine kinases, and affects the tumor and vasculature in preclinical models. Based on its pharmacologic effect, it may be a useful cancer treatme
Autor:
Alfred Furth, Charles Erlichman, Stephanie L. Safgren, Julian R. Molina, Chetan Lathia, Joel M. Reid, Jeff A. Sloan, Steven R. Alberts
Publikováno v:
Anti-Cancer Drugs. 16:997-1002
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade the extracellular matrix during the processes of invasion, metastasis and angiogenesis. BAY 12-9566 (BAY) is a selective, non-peptidic biphenyl inhibitor of MMPs, with na
Autor:
S. Huan, H. Hirte, E. Chouinard, Chetan Lathia, V. Agarwal, R. Humphrey, Sarah Matthews, David J. Stewart, S. Stafford, and L. Seymour, Rakesh Goel, B. Waterfield, Brian Schwartz
Publikováno v:
Investigational New Drugs. 23:437-443
Background: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin in patients with advanced solid tumours, and to identify the ma
Publikováno v:
Clinical Cancer Research. 11:5472-5480
Purpose: BAY 43-9006, a novel multikinase inhibitor, prevents tumor growth by combining two antitumor activities: inhibition of both tumor cell proliferation and tumor angiogenesis. This phase I, open-label, nonrandomized, noncontrolled, single-arm,
Autor:
Chetan Lathia
Publikováno v:
Disease Markers, Vol 18, Iss 2, Pp 83-90 (2002)
Disease Markers
Disease Markers
As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity
Publikováno v:
The Journal of Clinical Pharmacology. 41:764-769
The impact of age and gender on the single-dose pharmacokinetics, safety, and tolerability of BAY 12-9566 was evaluated in healthy subjects. Volunteers were grouped according to age and gender (13 young males, 11 elderly males, and 12 elderly females